Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Rani Therapeutics Holdings Inc

RANI ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.59

▼ -2.88%

Market Cap $81.91M · Vol 48.13K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$81.91M

Micro Cap

Div Yield

N/A

EPS Growth

+60.56%

YoY

RSI (14)

21.31

Momentum

Beta

0.58

vs Market

52W High

$2.63

84.37% below

52W Low

$0.58

0.17% above

Volume

48.13K

Avg 97.66K

P/B

3.99

Price-to-book

ROE

N/A

Return on equity

Free Float

95.10%

Public shares

Shariah Compliance8 STANDARDS

✗ Rani Therapeutics Holdings Inc (RANI) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RANI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-13.59%

-24.46%

-34.47%

-38.15%

YTD

-56.47%

-75.67%

-70.02%

-96.83%

Financials & Valuation

TTM · Annual

Total Revenue	$1.63M
Net Income	$-40,950,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-2,345.99%
Net Profit Margin	-2,507.65%
ROE	N/A
ROA · ROIC	-85.98% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	54.68
P/B	3.99
P/FCF	N/A
EPS Growth	+60.56%
Outstanding Shares	139.40M

Technical Indicators

50-Day SMA	$0.80
200-Day SMA	$0.96
RSI (14)	21.31
Beta	0.58
52-Week High	$2.63
52-Week Low	$0.58

Volume Today	48.13K
Avg Daily Volume (30D)	97.66K
Relative Volume	0.49x
Volatility (10D)	59.81
Volatility (30D)	70.80
Free Float	95.10%

Analyst Consensus

BUY

Current Price $0.59

Mean Target $6.25

52W Low$0.58 52W High$2.63

Current

Target

$0.58 $2.63

Current Analyst target

+963.65% upside potential · 4 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG011R6PZZ0

ISINUS7530181004

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 6, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).